Venture Visionary Partners LLC Has $6.83 Million Stock Position in Amgen Inc. $AMGN

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Venture Visionary Partners LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 51.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,920 shares of the medical research company's stock after selling 22,975 shares during the quarter. Venture Visionary Partners LLC's holdings in Amgen were worth $6,829,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Banco Bilbao Vizcaya Argentaria S.A. boosted its stake in shares of Amgen by 2.0% in the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 76,212 shares of the medical research company's stock valued at $23,720,000 after purchasing an additional 1,519 shares in the last quarter. JT Stratford LLC boosted its stake in shares of Amgen by 32.1% in the 1st quarter. JT Stratford LLC now owns 1,466 shares of the medical research company's stock valued at $457,000 after purchasing an additional 356 shares in the last quarter. Sumitomo Mitsui Financial Group Inc. boosted its stake in shares of Amgen by 10.3% in the 1st quarter. Sumitomo Mitsui Financial Group Inc. now owns 61,643 shares of the medical research company's stock valued at $19,205,000 after purchasing an additional 5,775 shares in the last quarter. bLong Financial LLC boosted its stake in shares of Amgen by 5.1% in the 1st quarter. bLong Financial LLC now owns 3,100 shares of the medical research company's stock valued at $966,000 after purchasing an additional 150 shares in the last quarter. Finally, Texas Capital Bancshares Inc TX acquired a new stake in shares of Amgen in the 1st quarter valued at $229,000. Institutional investors own 76.50% of the company's stock.

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president directly owned 8,162 shares of the company's stock, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares of the company's stock, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.76% of the stock is currently owned by corporate insiders.

Amgen Trading Down 0.7%

Shares of AMGN stock traded down $2.04 on Friday, reaching $293.72. The company had a trading volume of 1,643,970 shares, compared to its average volume of 2,104,120. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The stock has a market cap of $158.13 billion, a PE ratio of 24.02, a PEG ratio of 2.55 and a beta of 0.49. The company has a 50-day moving average of $293.43 and a 200-day moving average of $293.27. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $339.17.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. The company had revenue of $9.18 billion during the quarter, compared to analysts' expectations of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.Amgen's revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the business posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 22nd will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend is Friday, August 22nd. Amgen's dividend payout ratio is presently 77.84%.

Analyst Ratings Changes

AMGN has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Amgen from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Erste Group Bank downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Guggenheim initiated coverage on shares of Amgen in a research note on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 target price on the stock. Bank of America upped their price target on shares of Amgen from $252.00 to $261.00 and gave the stock an "underperform" rating in a research report on Wednesday, July 23rd. Finally, Mizuho upped their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 7th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $303.76.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.